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DOI 10.1186/s13075-017-1292-2RESEARCH ARTICLE Open AccessStructural predictors of response to
intra-articular steroid injection in
symptomatic knee osteoarthritis
Nasimah Maricar1,2,3, Matthew J. Parkes1,2, Michael J. Callaghan1,2,4, Charles E. Hutchinson5, Andrew D. Gait6,
Richard Hodgson6, David T. Felson1,2,7† and Terence W. O’Neill1,2,8*†Abstract
Background: The aim was to examine if structural factors could affect response to intra-articular steroid injections
(IASI) in knee osteoarthritis (OA).
Method: Persons with painful knee OA participated in an open-label trial of IASI where radiographic joint space
narrowing (JSN) and Kellgren-Lawrence (KL) grade, whole-organ magnetic resonance imaging (MRI) scores (WORMS)
and quantitative assessment of synovial tissue volume (STV) were assessed on baseline images. Participants completed
the Knee Injury and Osteoarthritis Outcome Score (KOOS) and a question about knee pain with a visual analogue
scale for pain during nominated activity (VASNA), and Outcome Measures in Rheumatology (OMERACT)-Osteoarthritis
Research Society International (OARSI) criteria were used to assess responder status within 2 weeks (short term) and
6 months (longer term). Regression models were used to examine predictors of short and longer term response to IASI.
Results: Subjects (n = 207) attended and had IASI. Information on responder status was available on 199 participants. Of
these, 188 subjects, mean age 63.2 years (standard deviation (SD) 10.3), 97 (51.6%) female, had x-rays and 120 had MRI
scans available. Based on the OMERACT-OARSI criteria, 146 (73.4%) participants responded to therapy and 40 (20.1%)
were longer term responders. A few factors were associated with a reduced KOOS-pain and VASNA response though
none were associated with OMERACT-OARSI responder status in the short term. Higher MRI meniscal damage (odds
ratio (OR) = 0.74; 95% CI 0.55 to 0.98), increasing KL maximal grade (OR = 0.43; 95% CI 0.23 to 0.82) and joint space
narrowing (JSN) maximal score (OR = 0.60; 95% CI 0.36 to 0.99) were each associated with a lower odds of longer term
responder status. Baseline synovitis was not associated with treatment response. The predicted probability of longer
term response decreased from 38% to 12% as baseline maximal JSN increased from grade 0 to 3.
Conclusion: Compared with those who have mild structural damage, persons with more severe knee damage on
either MRI or x-ray are less likely to respond to knee IASI.
Trial registration: ISRCTN.com, ISRCTN07329370. Registered 21 May 2010. Retrospectively registered
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Intra-articular steroid injection (IASI) is an effective [1],
widely used [2] and recommended treatment [3] for
individuals with symptomatic osteoarthritis (OA) of the
knee with short term pain relief lasting up to 3–4 weeks
compared with placebo injection [1, 4–6], with some
persons having longer term response up to 24 weeks
[4, 7]. There are, however, significant variations in
both the magnitude and duration of symptom relief
following steroid injections [1, 4, 5, 8]. Such variation may
be due to differences in the phenotypic expression, includ-
ing severity of the disease; however, there are few
published data on this issue and those studies that
have examined structural factors predicting response
have been small [6, 7, 9–14] and findings have been
discrepant [6–8, 11, 13, 15]. Further, only radio-
graphic [7, 9, 13, 15] and arthroscopic [7] predictor
factors have been studied. Also in one trial factors
predictive of IASIs were studied after combined treat-
ment with arthroscopic lavage [7].
In our recent open-label study of IASI in knee OA
[16], not all participants responded to the therapy in the
short term (within 2 weeks). Of those who responded in
the short term the majority, though not all, had a recur-
rence of pain within 6 months. As part of this study, we
examined whether factors representing structural fea-
tures of OA or of inflammation might identify persons
who were likely to respond to IASI either in the short or
longer term. Our study of IASI predictor of response
was larger in scale and longer in follow up than prior
studies, and also involved scoring of individual features
through contrast-enhanced (CE)-magnetic resonance
imaging (MRI), offering the opportunity to identify other
OA features and synovial factors affecting response to
IASI treatment. To optimize selection of persons for
IASI treatment, it would be helpful to separate re-
sponders from non-responders.
We hypothesised that those with more severe joint
damage would be less likely to respond, while those with
an underlying “inflammatory” phenotype characterised
by synovitis/effusion would be more likely to respond.
Using data from our study, we looked at the impact of
these “structural” factors based on radiographic and MRI
on response to therapy in the short and longer term.
Methods
Participants
Men and women (n = 209) aged 40 years and over were
recruited from primary and secondary care clinics for par-
ticipation in an open-label study examining the efficacy of
IASI in symptomatic knee OA (ISRCTN07329370). Sub-
jects were included if they reported moderate knee pain
for more than 48 hours in the previous 2 weeks on global
rating or scored more than 7 out of 32 on the Knee Injuryand Osteoarthritis Outcome Score (KOOS) [17], for ques-
tions P2–P9 (question P1 relates to frequency of knee
pain, which is irrelevant given the inclusion criteria on
pain frequency). Inclusion criteria included imaging con-
firmation of OA either radiologically in the index knee (in
any compartment on anteroposterior (AP), skyline or
lateral projection knee radiographs obtained within the
previous 2 years) with a Kellgren-Lawrence (KL) score of
2 or more or, on MRI scan or at arthroscopy. For MRI
and arthroscopy, we required typical changes of OA with
at least evidence of cartilage loss. Exclusion criteria in-
cluded gout, septic arthritis, inflammatory arthritis, hya-
luronic acid or steroid injection within the previous
3 months, knee surgery within the previous 6 months,
concurrent life threatening illnesses and any contraindica-
tion to MRI scanning.
Screening and baseline assessment
Subjects were assessed for eligibility at a screening visit
[16]. For those in whom previous knee imaging within the
previous 2 years was not available, radiographs of the
index knee were performed at the screening assessment.
Those who fulfilled the inclusion/exclusion criteria were
invited to attend baseline assessments. Subjects completed
a series of questionnaires including the KOOS-pain scale
[17], a global Likert scale and visual analogue scale (VAS)
for pain during an activity that a patient nominated as
being most troublesome (VASNA). For those subjects who
took part in the MRI sub-study, the MRI scans were
undertaken immediately prior to IASI. Following the MRI
scan the joint was injected with 80 mg methylpredniso-
lone acetate (without local anaesthetic) with aspiration of
synovial fluid in cases of clinical effusion. We treated and
studied one knee per participant.
Follow up
Short term and longer term response was assessed using
the Outcome Measures in Rheumatology-Osteoarthritis
Research Society International (OMERACT-OARSI) re-
sponder criteria based on the KOOS-pain scale and global
Likert scale [18]. A responder was defined as either (1)
greater or equal to 20% change in KOOS-pain score and a
“slightly” or “much better” score on the 5-point Likert
scale for change in pain, or (2) greater or equal to 50%
change in the KOOS-pain score; in both cases an absolute
change of at least 3 units if the baseline KOOS score was
15 or less. Participants were seen usually within 2 weeks
after the injection and we characterised their response
then as short term response. Based on these criteria those
who had not responded were not further followed up.
Those who responded were followed with regular tele-
phone calls during which the same KOOS-pain questions
and global Likert scale were administered. Those whose
pain rebounded to within 20% of the baseline KOOS-pain
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for a final follow up. Those whose pain levels did not re-
turn to this level at 6 months of follow up were classified
as “longer term responders”.
Magnetic resonance imaging: acquisition and analysis
Using a 3-T Philips MRI scanner, sagittal post-contrast
T1W FS (repetition time (TR) 550 ms, echo time (TE)
20 ms, field of view (FOV) 14 cm × 14 cm, size 320 ×
320) and sagittal pre-contrast 3-D WATSC (TR 20 ms,
TE 4.7 ms, FOV 15 cm × 15 cm, size 288 × 288) scans
were obtained. Semi-quantitative assessment of the MRI
images over 14 areas using the Whole-Organ Magnetic
Resonance Imaging Score (WORMS) was used by an
experienced musculoskeletal (MSK) radiologist to grade
effusion, cartilage, bone attrition, bone marrow lesion
(BML), synovitis, osteophytes, bone cyst, menisci and
ligaments within the knee, using an approach previously
described in which higher scores indicate greater severity
of the feature [19]. Synovitis was scored 0–1–2–3 ac-
cording to increasing synovial thickness [19]. Bone attri-
tion, BML, effusion and cyst were scored 0–3, cartilage
and menisci were scored 0–6 and osteophytes were
scored 0–7 in each of the 14 areas [20]. For all MRI fea-
tures, we used the maximal score, that is, the worst scor-
ing in any region of the knee. Synovitis and effusion
were scored using the sagittal contrast-enhanced (CE)
MRI sequence [19, 20]. Intra-reader reliability was
assessed by the same reader re-evaluating 19 films after
an interval period, with weighted kappa scores of 0.71,
0.70, 0.63, 0.77, 0.88, 0.77 and 0.91 for cartilage, cysts,
osteophytes, BMLs, menisci, synovitis and effusion, re-
spectively. The CE images were then assessed quantita-
tively for synovial tissue volume (STV) [16]. To evaluate
repeatability of assessment of synovial volumes, the
segmenter was asked to segment 10 knees randomly se-
lected (without replacement) from those that had been
previously segmented with new identification numbers
assigned [16]. The intra-class correlation coefficient
(ICC) for intra-reader reliability of the manual segmen-
tation was 0.94.
Radiographs
Knee radiographs were evaluated by an experienced
MSK radiologist (CEH) who scored the KL and joint
space narrowing (JSN) grades on skyline, weight-bearing
AP and lateral projection radiographs of all participants
for whom films were available. The KL and JSN grades
were scored separately with KL scores 0–4 to denote the
increasing level of joint degeneration [21], while JSN 0–
3 indicated none, mild, moderate and severe reduction
in joint space [22]. We looked also at anatomic mal-
alignment. This was assessed on weight-bearing AP ra-
diographs by one assessor (NM) using software installedwithin the hospital imaging system by calculating the
angle from the intersection of the line from the mid-
point of tibial spines bisecting the femoral shaft with the
line from the midpoint of the tibial spines bisecting the
tibial shaft [23]. The ICC was 0.99 for intra-rater reliabil-
ity in the measurement of knee mal-alignment angle
performed 3 months apart through random generated
numbers of 50 images.
Statistical analysis
Subject characteristics were summarised using means
and standard deviations (SD) for normally distributed
variables and medians and interquartile ranges (IQR) for
variables with a skewed distribution. We used the paired
t test to look for change in pain, assessed using the
KOOS and VASNA between baseline and the post-
injection visit. We used a fixed-effects panel regression
model to examine whether there was any association be-
tween the baseline structural factors and change in pain,
a continuous outcome variable (assessed using both
KOOS and VASNA) between baseline and initial follow
up. For effusion, cartilage, bone attrition, BML, synovitis,
osteophytes, bone cyst, menisci and ligaments we fo-
cused our analyses on the maximal WORMS for that
feature and we included it in the model as a continuous
variable; results were expressed as unstandardized b-
coefficients and 95% confidence interval (CI). Logistic
regression was used to determine whether baseline im-
aging parameters were associated with both short term
and also longer term responder status (yes/no as out-
come) to therapy. Results were expressed as odds ratios
(OR) and 95% CI. Each factor of interest was investi-
gated separately using a bivariate model, with either
short term or longer term responder status as the out-
come, and the factor of interest as the predictor variable.
Data for short term and longer term response were
analysed using a maximal case analysis using all avail-
able data for all variables. To examine the predictive
probability of responder status (short/longer term),
we extracted the predictive probabilities using the lo-
gistic regression model. Statistical analyses were
undertaken using Stata version 13.1 (StataCorp, Col-
lege Station, TX, USA).
Results
Participants
We recruited 209 participants. Two participants were
withdrawn following recruitment and before treatment for
receiving IASI from their General Practitioners (GPs) (see
Fig. 1); 207 participants participated in the trial and re-
ceived IASI. A further 8 subjects were later withdrawn for
reasons listed in Fig. 1, with 199 participants remaining.
Of these, 188 subjects had knee radiographs, mean age
was 63.2 years (SD: 10.3 years) and 51.6% were female (see
Fig. 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart of participants for assessments of radiographs and
magnetic resonance imaging (MRI) scans. GP General Practitioner, CE contrast-enhanced
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points (IQR: 36.1–55.6), and median VASNA was 7.0 cm
on a 0–10 cm scale (IQR: 5.6–8.1). For all participants, the
median time between baseline and post-injection follow
up was 8 days (IQR: 7–14). Of the 120 participants who
had MRI, it was possible to assess WORMS in 109 partici-
pants and synovial tissue volume in 111 participants.Imaging characteristics
Of those with radiographs, 36.7% of participants had
overall KL grade 2 at the knee, 53.7% had KL grade 3
and 9.6% had KL grade 4 (see Table 2). For JSN, we con-
sidered the scores in the medial tibiofemoral (TF), lateral
TF and patellofemoral (PF) compartments and an overall
JSN maximal score (any compartment). Overall 1.6%
had a JSN maximal score of zero, 31.6% a JSN score of1, 48.1% a JSN score of 2 and 18.7% a JSN score of 3.
Table 2 shows the distribution of the maximal score for
the MRI features including BML, meniscal damage, effu-
sion, synovitis, cartilage, osteophytes and attrition.Structural parameters and change in pain
At 2 weeks post injection, knee pain significantly im-
proved when assessed by KOOS (+23.7 points; 95% CI:
20.9 to 26.5; p < 0.001) and VASNA (-3.3 cm; 95% CI: -3.8
to -2.9; p < 0.001). Among those with MRI scans, those
with a higher maximal BML score (b coefficient = 0.76,
95% CI 0.16 to 1.36) and maximal meniscal damage score
(b coefficient = 0.37, 95% CI 0.04 to 0.70) had less im-
provement in pain as determined by VASNA (see Table 3).
Similarly, among those with radiographs, higher TF and
PF KL scores, higher overall KL maximal score, higher PF
Table 1 Participant characteristics
Variable MRI cohort Radiograph cohort
Number 120a 188
Age (years), mean (SD) 62.3 (10.3) 63.2 (10.3)
Female, frequency (%) 62 (51.7) 97 (51.6)
Number of days to follow-up appointment, median (IQR) 8.0 (7.0–14.0) 8.0 (7.0–14.0)
KOOS-pain subscale score (0–100)b, median (IQR) 44.4 (36.1–55.6) 44.4 (36.1–55.6)
Pain on nominated activity, VASNA (0–10 cm)
c, median (IQR) 7.0 (5.5–7.7)d 7.0 (5.6–8.1)e
Pain in last week, VAS (0–10 cm)c, median (IQR) 6.5 (4.7–7.8)d 6.5 (4.9–8.0)e
Responders to injection, at follow-up visit, frequency, (%) 85 (70.8) 137 (72.9)
MRI magnetic resonance imaging, SD standard deviation, IQR interquartile range, CI confidence interval, KOOS Knee Injury and Osteoarthritis Outcome Score, VAS
visual analogue scale, VASNA VAS for pain during nominated activity.
aThere were 109 baseline images available for assessment of Whole Organ Magnetic
Resonance Imaging Score and 111 available for assessment of synovial tissue volume; bKOOS pain subscale is scored from 100 (no pain) to 0 (extreme pain); cVAS
is scored from 0 cm (no pain) to 10 cm (pain as bad as you can imagine); dthere were 5 and 3 patients who did not complete their VASNA and VAS for pain in the
last week, respectively; ethere were 8 and 4 patients who did not complete their VASNA and VAS for pain in last the week, respectively
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sociated with less improvement in pain as assessed using
VASNA (see Table 3). The presence of synovitis assessed
using WORMS and also STV assessed quantitatively was
not associated with change in pain. For pain assessed
using KOOS, the results in relation to structural predic-
tors were in the same direction though they were not sta-
tistically significant. Mal-alignment was not associated
with response.
Predictors of responder status
Short term response
At short term follow up 146 (73.4%) of the 199 partici-
pants were OMERACT-OARSI responders. None of the
MRI or radiographic variables was associated with
OMERACT-OARSI responder status at short term fol-
low up (see Table 4).
Longer term response
Of the 146 participants who were short term responders,
6 did not attend for a final visit. Of those who did, 100Table 2 MRI and radiographic features at baseline
Maximal score MRI features (WORMS)
BML (n) Menisci (n) Effusion (n) Synovitis (n) C
0 5 35 22 0 5
1 30 0 46 2 5
2 26 9 32 18 9
2.5 - - - - 1
3 48 24 9 89 8
4 41 2
5 0 3
6 0 1
7
MRI magnetic resonance imaging, WORMS Whole organ magnetic resonance imagin
narrowing. WORMS range of scores differs for each feature. aMaximal score in any r
JSN scoringhad a recurrence of pain during the following 6 months,
while 40 were longer term responders. Higher maximal
score for meniscal damage, and higher radiographic TF
KL score, overall KL maximal score and overall JSN
maximal score were associated with decreased odds of
being a longer term responder (see Table 4).
Predicted probability of response
Depending on the structural predictor, as disease sever-
ity increased there was a trend towards a reduced prob-
ability of being a responder to IASI. For instance, the
probability of being a short term responder to IASI de-
creased from 82% (95% CI 69% to 95%) among those
with an overall JSN maximal score of 0, to 66% (95% CI
53% to 79%) among those with a JSN maximal score of
3, though this difference was not statistically significant
(see Table 5). In the longer term there was a significant
threefold decrease in the chance of being a longer term
responder to IASI when the overall JSN maximal scores
increased from 0 (38%; 95% CI 16% to 60%) to 3 (12%;
95% CI 4% to 19%) and a fivefold decrease when theRadiographic features
artilage (n) Osteophyte (n) Attrition (n) KLa (n) JSNa (n)
0 3 0 3
1 19 0 59
10 49 69 90
0 - - - -
19 38 101 35
6 25 18
6 16
0 33
5
g score, BML bone marrow lesion, KL Kellgren-Lawrence, JSN joint space
egion; 188 participants with available images for KL grading and 187 for
Table 3 Baseline imaging characteristics and their relation to change in pain at 2 weeks among persons treated with intra-articular
steroids
Predictor variable in regression KOOS pain score Pain on nominated activity VAS
N b coefficient (95% CI)c P value N b coefficient (95% CI)d P value
MRI (WORMS)
Synovitis maximal score (0–3) 109 -1.94 (-11.15 to 7.26) 0.677 96 0.45 (-0.83 to 1.74) 0.487
Bone marrow lesion maximal score (0–3) 109 -3.48 (-7.76 to 0.80) 0.110 96 0.76 (0.16 to 1.36)* 0.013
Bone attrition maximal score (0–3) 109 -1.78 (-6.98 to 3.42) 0.498 96 -0.07 (-0.81 to 0.66) 0.846
Cartilage damage maximal score (0–6) 109 0.09 (-2.55 to 2.72) 0.948 96 0.16 (-0.20 to 0.53) 0.378
Cyst maximal score (0–3) 108 0.56 (-4.48 to 5.60) 0.827 95 0.27 (-0.48 to 1.01) 0.475
Menisci damage maximal score (0–6) 109 -2.12 (-4.49 to 0.25) 0.079 96 0.37 (0.04 to 0.70)* 0.027
Osteophyte maximal score (0–7) 109 0.56 (-2.23 to 3.36) 0.690 96 0.18 (-0.22 to 0.57) 0.377
Synovial effusion (0–3) 109 -1.22 (-5.90, 3.46) 0.608 96 0.17 (-0.49 to 0.83) 0.606
MRI (quantitative)
Synovial tissue volume (1000 mm3) 111 -0.05 (-0.67 to 0.57) 0.883 98 0.03 (-0.05 to 0.12) 0.408
Radiographs
Tibiofemoral KL score (0–4) 186 -2.40 (-6.80 to 2.00) 0.284 170 0.66 (0.02 to 1.30)* 0.042
Patellofemoral KL score (0–4) 187 -0.001 (-3.16 to 3.16) 0.999 171 0.64 (0.18 to 1.10)* 0.006
Overall KL maximal scorea (0–4) 187 -1.97 (-6.64 to 2.71) 0.408 171 0.94 (0.27 to 1.62)* 0.007
Lateral tibiofemoral JSN score (0–3) 185 -0.001 (-4.12 to 4.12) 1.000 169 0.05 (-0.56 to 0.67) 0.865
Medial tibiofemoral JSN score (0–3) 186 -1.26 (-5.17 to 2.65) 0.524 170 0.21 (-0.38 to 0.79) 0.486
Patellofemoral JSN score (0–3) 178 -0.52 (-3.60 to 2.56) 0.738 162 0.52 (0.06 to 0.98)* 0.026
Overall JSN maximal scoreb (0–3) 186 -1.34 (-5.26 to 2.57) 0.499 170 0.72 (0.14 to 1.29)* 0.015
Knee mal-alignment angle (per degree) 191 0.03 (-0.53 to 0.59) 0.924 173 -0.04 (-0.13 to 0.04) 0.291
KOOS Knee Injury and Osteoarthritis Outcome Score, VAS visual analogue scale, MRI magnetic resonance imaging, WORMS Whole Organ Magnetic Resonance
Imaging Score, KL Kellgren-Lawrence, JSN joint space narrowing. Results shown are from fixed panel regression. amaximal KL grade of the tibiofemoral or patellofemoral
joint; bmaximal JSN score of the lateral or medial tibiofemoral or patellofemoral joint; cKOOS pain score ranges from 0–100 with lower scores representing more severe
pain. Negative coefficients signify that more severe imaging findings were associated with less pain improvement; dpain on nominated activity ranged from 0 to 10 with
higher values representing more severe pain. Positive coefficients signify that more severe imaging findings were associated with less pain improvement. *Represent
results that are significant at p < 0.05
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14% to 43%) to 6 (6%; 95% CI 0% to 13%).
Discussion
In this study, 73.4% of participants were short term re-
sponders after an IASI, while one in four was a longer
term responder. Using OMERACT-OARSI criteria as
our definition of response, we found no short term
structural predictors of response. Increasing disease se-
verity as determined by MRI and plain radiographs was
associated with longer term non-responder status.
Radiographic markers of disease severity including
higher KL and JSN scores were associated with poorer
response to IASI in the short term as defined by a
change in VASNA. Similarly, MRI features were also
linked with response, with features suggestive of more
structural damage being linked with a poorer short term
response.
There are few studies that have looked at the influence
of structural factors on response to IASI. In a systematic
review we found a paucity of data on predictors ofresponse to IASI and inconsistent results relating to dis-
ease severity [8]. The findings of the current study are
consistent with two studies where increasing radio-
graphic severity of OA was linked with reduced response
[7, 15]. Smith et al. [7] in a study of 38 patients with
knee OA who received 120 mg methylprednisolone acet-
ate preceded by arthroscopy, found that severity was
linked with reduced OARSI response at 4 weeks, while
in a study of 79 participants with OA, higher radio-
graphic grade was linked with less improvement in
Western Ontario and McMaster Universities Osteoarth-
ritis Index (WOMAC) pain score at 26 weeks (p < 0.05);
however, the analysis was based on combined outcome
of their steroid and lavage/tidal irrigation groups [15]. In
contrast, two other studies did not find that radiographic
OA grading predicted short term response (<6 weeks) to
IASI in knee OA when VAS pain was used as the out-
come [9, 13]. The small sample size of these studies
(16–42 participants) might have contributed to low
power to detect response [9, 13]. Another factor, which
may have explained the potential discrepancy, is the dose
Table 4 Prediction of responder status at short term (2 weeks) and longer term (6 months) follow up, by baseline imaging
characteristics
Predictor variable in regression Short term responder at 2 weeks (yes/no) Longer term responder at 6 months (yes/no)
N Odds ratio (95% CI) P value N Odds ratio (95% CI) P value
MRI (WORMS)
Synovitis maximal score (0–3) 109 0.82 (0.32 to 2.13) 0.689 109 0.43 (0.17 to 1.12) 0.084
Bone marrow lesion maximal score (0–3) 109 0.76 (0.49 to 1.19) 0.231 109 1.12 (0.66 to 1.92) 0.668
Bone attrition maximal score (0–3) 109 0.94 (0.56 to 1.57) 0.804 109 0.59 (0.32 to 1.10) 0.097
Cartilage damage maximal score (0–6) 109 0.98 (0.75 to 1.27) 0.869 109 1.03 (0.74 to 1.42) 0.873
Cyst maximal score (0–3) 108 0.74 (0.46 to 1.20) 0.222 108 1.27 (0.72 to 2.22) 0.408
Menisci damage maximal score (0–6) 109 0.95 (0.74 to 1.20) 0.647 109 0.74 (0.55 to 0.98)* 0.039
Osteophyte maximal score (0–7) 109 1.13 (0.86 to 1.49) 0.386 109 0.98 (0.70 to 1.38) 0.919
Synovial effusion (0–3) 109 0.83 (0.52 to 1.31) 0.420 109 0.79 (0.44 to 1.41) 0.421
MRI (quantitative)
Synovial tissue volume (per 1000 mm3) 111 1.00 (1.00 to 1.00) 0.612 111 0.96 (0.88 to 1.04) 0.327
Radiographs
Tibiofemoral KL score (0–4) 187 0.79 (0.49 to 1.28) 0.341 187 0.52 (0.30 to 0.91)* 0.021
Patellofemoral KL score (0–4) 188 0.86 (0.60 to 1.22) 0.391 188 0.80 (0.54 to 1.19) 0.269
Overall KL maximal scorea (0–4) 188 0.72 (0.43 to 1.20) 0.205 188 0.43 (0.23 to 0.82)* 0.010
Lateral tibiofemoral JSN score (0–3) 186 1.27 (0.79 to 2.03) 0.327 186 0.86 (0.51 to 1.45) 0.569
Medial tibiofemoral JSN score (0–3) 187 0.91 (0.59 to 1.40) 0.661 187 0.69 (0.42 to 1.15) 0.154
Patellofemoral JSN score (0–3) 179 0.83 (0.59 to 1.16) 0.265 179 0.85 (0.56 to 1.28) 0.425
Overall JSN maximal scoreb (0–3) 187 0.75 (0.49 to 1.16) 0.196 187 0.60 (0.36 to 0.99)* 0.047
Knee mal-alignment angle (per degree) 192 0.98 (0.92 to 1.04) 0.481 192 1.01 (0.94 to 1.08) 0.801
MRI magnetic resonance imaging, WORMS Whole Organ Magnetic Resonance Imaging Score, KL Kellgren-Lawrence, JSN joint space narrowing. Results presented
are from logistic regression. amaximal KL grade of the tibiofemoral or patellofemoral joint; bmaximal JSN score of the lateral or medial tibiofemoral or
patellofemoral joint. *Represent results that are significant at p < 0.05
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either 40 mg of triamcinolone acetonide or 120 mg
methylprednisolone acetate [7, 15], while the two that
did not show any association of severity of disease with
response used a smaller dose - 20 mg triamcinolone
hexacetonide [9, 13]. Further, the focus of prior studies
on short term outcomes may have also made it difficultTable 5 Predictive probabilities of being a short term and longer te
Probability
Overall KL maximal gradea 0 1
Short term predicted probabilityb 0.87d 0.83d
Longer term predicted probability 0.69d 0.49d
Overall JSN maximal scorec 0 1
Short term predicted probabilityb 0.82 0.77
Longer term predicted probability 0.38 0.27
Menisci maximal WORMS 0 1
Short term predicted probability 0.72 0.70
Longer term predicted probability 0.28 0.22
KL Kellgren-Lawrence, JSN joint space narrowing, WORMS Whole Organ Magnetic Reso
joint; btrend not statistically significant; cmaximal JSN score of the lateral or medial tibifor these studies to detect an association between disease
severity and outcome, as the large majority of patients
respond over the short term. Additionally no previous
studies have examined both short term and longer term
predictors of outcomes within the same trial. In our
study we found no significant associations between
structural damage and short term response as defined byrm responder: radiographs and MRI features
2 3 4
0.78 0.71 0.64
0.29 0.15 0.07
2 3
0.72 0.66
0.18 0.12
2 3 4 5 6
0.69 0.68 0.67 0.66 0.64
0.18 0.14 0.10 0.08 0.06
nance Imaging Score; amaximal KL grade of the tibiofemoral or patellofemoral
ofemoral or patellofemoral joint; dvalues based on modelling
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gesting a poorer response) was similar to that observed
for the VASNA.
To our knowledge, this is also the first study to have
looked at MRI predictors of response. The results are
consistent with the radiographic findings, though
perhaps because of smaller numbers in the responder
analysis, not all MRI features attained statistical signifi-
cance. The association between higher meniscal damage
with a lesser reduction in pain in the short term, and
also reduced odds of being a longer term responder, is
consistent with greater meniscus damage being associ-
ated with greater severity of OA disease [24]. Larger
BMLs were also associated with a lesser reduction in
pain in the short term; previous studies have shown that
increase in the size of BMLs is associated with increased
severity of joint degeneration [25–27].
At the outset, we hypothesised that there would be a
link between synovitis and response, with those with
greater baseline synovitis being more likely to respond;
however, we did not find this in the study. The mechan-
ism of the therapeutic effect of corticosteroids in knee
OA is unclear, though it has been thought likely related
in part to their potent anti-inflammatory effect. We have
already shown correlation between change in STV,
which is a marker for synovitis, and change in pain, in a
previous paper [16] and had expected to find a link be-
tween baseline synovitis and response. The most plaus-
ible explanation for the apparent discordant findings is
that any within-person change in pain due to reduced
synovitis is masked by other sources of between-person
variations in levels of pain including structural factors.
The null findings, though, are in keeping with observa-
tions made in previous studies that used either clinical
or ultrasound assessment of synovial hypertrophy and
power Doppler assessment of synovitis [6, 10, 11].
The presence of an effusion on MRI was not a pre-
dictor of response. Previous studies that correlated posi-
tive response to IASI with effusion had used clinical
assessment to detect knee effusion [9, 15], though one
other study that used clinical assessment of effusion
found no such correlation [10]. Non-contrast ultrasound
assessment of effusion has not been shown to predict
response [6, 11].
In our study, the early-responder rate (73.4%) was
similar to most though not all studies [1]. There are
much fewer data on longer term response. We found
20% of participants maintained their improvement in
pain for at least 6 months. This is consistent with Arden
et al. [15] who reported that 29% of participants main-
tained improvement at their 6-month follow up. Smith
et al. [7] reported a higher (42% or 16 participants)
longer term responder rate at 6 months; it is possible
this could be explained by the higher dose of steroidused (120 mg methylprednisolone acetate) and also by
the fact that 30 out of their 38 participants received a
second course of IASI at the time of relapse during the
period of the study.
Using radiographic and MRI data, we derived a pre-
dictive table, though the short term radiographic predic-
tion probabilities should be viewed with caution given
their non-significant results and their wide CIs. Our
predictive probabilities suggest people with advanced
radiographic disease are unlikely to benefit from IASI in
the longer term. Based on the degree of JSN observed
on radiographs, the odds of having longer term response
is increased from around 10% to almost 40% as the
disease becomes less severe.
Our study is the largest yet performed looking at re-
sponse to IASI. There are some limitations to be consid-
ered in interpreting the analysis. The study included
individuals who received steroid injections only and it is
likely that the overall response to the injection is at least
in part due to a “placebo” effect. It seems, however, very
unlikely that this can explain our findings relating to
factors identified as predicting response. As noted previ-
ously, earlier studies of intra-articular steroids without a
control group have not reported an association between
structural severity and response, and while structural
severity has been linked to a worse pain trajectory in
some studies [28], other longitudinal studies have re-
ported no association between baseline structural sever-
ity and the trajectory of pain [29, 30]. In relation to limb
mal-alignment we used conventional non-standardised
images to estimate the angle and did not use a full-limb
weight-bearing radiograph, which is a gold standard for
measuring knee mal-alignment; it is possible that mis-
classification may have resulted in a bias of the results
towards the null. There is, however, evidence of strong
correlation between the femur-tibia angle measured
from knee radiographs with hip-knee-ankle angle mea-
sured from full-limb radiographs (r = 0.86; 95% CI: 0.81
to 0.90) [23].
Our MRI sequences were optimised for the detection of
BMLs, which may have contributed to our negative find-
ings with the other knee structures. Further, radiographs
in the study could have been taken up to 24 months prior
to the IASI and it is possible that progression of disease
may have led to some misclassification of radiographic
disease severity with underestimation of OA severity in a
small proportion of subjects. Based on data from the
MOST study we estimate that over a 24-month period up
to 20% of subjects would have KL progression; however,
for most subjects in our study the time interval was sig-
nificantly shorter [31]. It is possible, however, that this
may have had a small impact on the predictive probabil-
ities observed. Some subjects did not complete the pain
questions at baseline and follow up. We have repeated the
Maricar et al. Arthritis Research & Therapy  (2017) 19:88 Page 9 of 10analysis using complete case analysis based on data from
participants with complete data on all variables with simi-
lar results to the maximal case analysis.
Conclusion
Over two thirds of people with painful knee OA respond
significantly in the short term to IASI and one in four
have persisting benefit beyond 6 months. Those with more
severe knee joint damage are less likely to respond to knee
IASI in the longer term. In contrast, the presence of
synovitis/effusion does not appear to predict successful
response to steroid injection therapy.
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